RA0449

antibody from Oursmab

Targeting: KLRC1 CD159a, NKG2, NKG2-A, NKG2-B

Immunocytochemistry

Flow cytometry

Functional assay

Antibody data

Submit

Validation data

Product number: RA0449 - Provider product page
Provider: Oursmab
Product name: Monalizumab (Biosimilar Reference Antibody) (KLRC1)
Antibody type: Monoclonal
Description: Monalizumab (also known as IPH-2201) is an investigational, humanized IgG4 monoclonal antibody that targets the immune checkpoint receptor NKG2A (CD159a). NKG2A forms a heterodimer with CD94 and is expressed on natural killer (NK) cells and a subset of CD8+ T cells. It binds to the non-classical MHC class I molecule HLA-E, which is often upregulated on tumor cells and infected cells. By blocking the interaction between NKG2A and HLA-E, monalizumab releases the inhibitory signal on NK cells and T cells, thereby enhancing their cytotoxic activity against tumors. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors and hematologic malignancies, often in combination with other therapies (e.g., anti-PD-L1 antibodies).
Reactivity: Human
Isotype: IgG
Vial size: 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration: Bottled at the concentration indicated on the vial.
Storage: Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

KLRC1 protein structure - RA0449 shown in red.